Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCANTM) in subjects with clinically uncertain parkinsonian syndromes

Table 2 Efficacy parameters for prediction of clinical diagnosis 1 year post scan: modified H&Y stage ( n = 92)

Subjects with CUPS	Clinical diagnosis at 1 year post-scan
	Subgroup: modified H&Y stage <2			Subgroup: modified H&Y stage ≥2
	PS	Non-PS	Total	PS	Non-PS	Total
Abnormal ioflupane [ ¹²³ I] images ^a	26	0	26	20	2	22
Normal ioflupane [ ¹²³ I] images	2	20	22	1	21	22
Total	28	20	48	21	23	44
Statistic	Result	Exact 95% CI		Result	Exact 95% CI	P value/analysis method ^b
Sensitivity ^c	0.9286	(0.7650, 0.9912)		0.9524	(0.7618, 0.9988)	1.0000
Specificity ^d	1.0000	(0.8316, 1.0000)		0.9130	(0.7196, 0.9893)	0.4906
Accuracy	0.9583	(0.8575, 0.9949)		0.9318	(0.8134, 0.9857)	0.6673
Positive predictive value	1.0000	(0.8677, 1.0000)		0.9091	(0.7084, 0.9888)	0.2048
Negative predictive value	0.9091	(0.7084, 0.9888)		0.9545	(0.7716, 0.9988)	1.0000

CI, confidence interval; CUPS, clinically uncertain parkinsonian syndrome; H&Y, Hoehn and Yahr; PS: parkinsonian syndrome. ^aAbnormal imaging types 1, 2 and 3. ^b P value is based on Fisher’s exact test. ^cSensitivity is equivalent to positive percent agreement. ^dSpecificity is equivalent to negative percent agreement.

ISSN: 1758-9193